B.A.S.M. Regional Conference - report

Por Keating, M. J
Publicado em 1965

Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes

Por Cervantes-Gomez, F, Patel, V Kumar, Bose, P, Keating, M J, Gandhi, V
Publicado no Leukemia (2016)

Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence.

Por Haidar, M A, Loya, F, Yang, Y, Lin, H, Glassman, A, Keating, M J, Goldwasser, E, Albitar, M
Publicado em 1996

Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Por Kantarjian, H M, Barlogie, B, Keating, M J, Hall, R R, Smith, T L, McCredie, K B, Freireich, E J
Publicado em 1985

Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response

Por Mould, D R, Baumann, A, Kuhlmann, J, Keating, M J, Weitman, S, Hillmen, P, Brettman, L R, Reif, S, Bonate, P L
Publicado em 2007

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia

Por Falchi, L., Vitale, C., Keating, M. J., Lerner, S., Wang, X., Elhor Gbito, K. Y., Strom, S., Wierda, W. G., Ferrajoli, A.
Publicado no Ann Oncol (2016)

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)

Por Jiang, Y, Chen, H-C, Su, X, Thompson, P A, Liu, X, Do, K-A, Wierda, W, Keating, M J, Plunkett, W
Publicado no Blood Cancer J (2016)